Minor Cannabinoids Explained: CBG, CBN, THCV, CBC, and CBDV

As minor cannabinoids flood the wellness market with sweeping health claims, an honest look at the science reveals early promise, persistent myths, dose-dependent complexity, and a significant gap between preclinical findings and human evidence.

Minor cannabinoids are cannabis compounds produced in smaller quantities than THC and CBD — including CBG, CBN, THCV, CBC, and CBDV — each with distinct receptor activity in the endocannabinoid system and an emerging body of clinical research. The hemp-derived cannabinoids shelf at your local dispensary or wellness shop has expanded fast. CBG tinctures, CBN sleep gummies, THCV capsules marketed as appetite suppressants: these products make confident claims about anxiety, sleep, appetite, and metabolism. Some of those claims rest on real, if early, science. Others rest on rodent studies or decade-old trials with sample sizes too small to draw conclusions from. Knowing the difference helps you make smarter decisions and have a more productive conversation with your doctor.

This article covers the five minor cannabinoids with the most research: CBG, CBN, THCV, CBC, and CBDV. For each, you’ll find an accurate account of the mechanism, the human evidence, and the gaps that remain.

Why Minor Cannabinoid Research Lags the Market

The U.S. minor cannabinoids market reached an estimated $11.5 billion in 2023 and is projected to grow 15% annually through 2030. Producers have responded to that demand by isolating minor phytocannabinoids and marketing them with therapeutic language that outpaces what clinical trials can currently support.

The research barriers are real. Schedule I federal classification has restricted funding, slowed approvals, and made supply difficult to standardize. A comprehensive 2021 pharmacology review covering the full minor cannabinoid landscape notes that most mechanistic data comes from in vitro models and animal research, with human clinical evidence lagging considerably behind. Progress is accelerating, but a single pilot trial does not confirm a treatment. It’s also worth keeping in mind that most hemp-derived cannabinoid products contain combinations of compounds — and the science on how minor cannabinoids interact with one another, sometimes called the entourage effect, is even younger than the science on each compound alone.

CBG (Cannabigerol): The Strongest Early Signal

CBG has the most credible emerging human evidence of any minor cannabinoid, though that evidence base is still thin. A 2024 double-blind, placebo-controlled crossover trial enrolled 34 healthy adults, who received either 20 mg of hemp-derived CBG or a placebo, and were assessed on anxiety, stress, mood, and cognition. CBG significantly reduced anxiety ratings at 20, 45, and 60 minutes after ingestion compared to placebo. Participants also recalled more words on a verbal memory task after CBG than after placebo, with no cognitive impairment or intoxicating effects. The lead researcher cautioned that replication and further research are needed before firm claims can be made.

A November 2024 comprehensive review of CBG’s molecular mechanisms documents its interactions with CB1, CB2, TRP channels, and alpha-2-adrenoceptors across preclinical models of inflammation, pain, and neurodegeneration. That multi-receptor pharmacology profile distinguishes CBG from CBD and gives researchers several plausible mechanisms to test in future human trials.

Worth noting: A sample of 34 adults in a remote field trial is a proof-of-concept, not a confirmed clinical finding. CBG for anxiety is promising. It is not established.

CBN (Cannabinol): Sleep Claims vs. Sleep Evidence

CBN sells as a sleep aid. That reputation has a weak foundation. A 2021 systematic review of all published human CBN studies concluded the clinical evidence for CBN’s sleep-promoting effects was insufficient. Most of the human research was conducted in the 1970s and 1980s, with small samples and limited diversity. Published clinical trials using validated sleep questionnaires or formal polysomnography were not found. The “sleepy cannabinoid” association likely traces to degraded terpenes in aged cannabis flower, not to CBN acting on its own.

Newer trials offer a more nuanced picture. A 2024 double-blind, randomized, placebo-controlled study of 293 participants found that 20 mg of CBN over seven nights reduced nighttime awakenings and overall sleep disturbance compared to placebo, but produced no significant effect on sleep onset. That distinction matters: reducing nighttime awakenings is a different outcome than helping you fall asleep. CBN has not been established as a sedative.

THCV (Tetrahydrocannabivarin): Metabolic Promise, Real Complexity

THCV has more human metabolic data behind it than most minor cannabinoids, and that data carries an important caveat. THCV acts as a CB1 receptor antagonist at low doses and as an agonist at higher doses. A dose-ranging, placebo-controlled trial in healthy adults found that 100 and 200 mg doses produced increased ratings of feeling a drug effect and scores on the ARCI Marijuana scale. Products marketing THCV as categorically non-psychoactive require qualification: dose determines psychoactivity.

On the metabolic side, a randomized controlled trial of 62 people with type 2 diabetes compared THCV, CBD, and placebo over 13 weeks. THCV showed favorable effects on fasting glucose and adiponectin levels compared to placebo, while the combination of CBD and THCV did not produce favorable effects for either compound. A 2025 review synthesizing THCV’s metabolic mechanisms concludes it may modulate appetite and glycemic control, while noting that larger-scale studies are necessary to confirm clinical efficacy and safety.

CBC and CBDV: Two Minor Cannabinoids With a Long Road Ahead

Cannabichromene (CBC) has no published human clinical trials. Preclinical signals cover anti-inflammatory, antidepressant-like (in rodent models), and neuroprotective activity. A 2024 pharmacological review of CBC documents its receptor profile, pharmacokinetics, and the near-total absence of human clinical data. CBC does not bind significantly to CB1 or CB2 receptors, instead acting through TRP channels and CB2 partial agonism. That mechanism gives researchers a rationale to study it, but no human trial has tested those signals yet.

Cannabidivarin (CBDV) sits further along. The 2021 minor cannabinoids pharmacology review highlights CBDV’s activity at TRPV1 and TRPA1 channels and its structural similarity to CBD. A Phase 2 randomized controlled trial has demonstrated CBDV’s tolerability in adults with focal seizures, and an ongoing trial at Montefiore Medical Center is testing CBDV in 100 children with autism spectrum disorder over 12 weeks. CBDV has a clinical pipeline, which puts it ahead of most compounds in this category.

The 2025 Regulatory Shift Reshaping Minor Cannabinoid Products

Section 781 of the 2025 Continuing Resolution amends the federal definition of hemp to account for total THC content rather than delta-9 THC alone, and it excludes cannabinoids synthesized outside the cannabis plant from the hemp definition. The FDA was required to publish a list of naturally occurring cannabis cannabinoids within 90 days of enactment. That shift will affect how producers formulate and label minor cannabinoid products, particularly semi-synthetic variants like converted delta-8.

A 2024 systematic review of minor cannabinoids in psychiatric disorders found only 22 preclinical studies and one qualifying clinical study across all compounds combined. That number frames what the regulatory moment means in practical terms: the science has not caught up to the market, and the new rules will raise the bar on what producers can claim. For consumers, the clearest takeaway is to treat bold therapeutic language on minor cannabinoid labels with appropriate skepticism until larger human trials confirm the signals that early research suggests.

Frequently Asked Questions

Are minor cannabinoids psychoactive?

It depends on the cannabinoid and the dose. CBG and CBD do not produce intoxication at currently studied doses. THCV acts as a CB1 antagonist at low doses but may produce THC-like subjective effects at doses of 100 mg or higher, based on dose-ranging trials in healthy adults. Labeling THCV as categorically non-psychoactive is not accurate.

Is CBN actually a sedative?

The evidence does not establish CBN as a sedative. A 2024 randomized controlled trial found CBN reduced nighttime awakenings but had no significant effect on how quickly participants fell asleep. The “sleepy cannabinoid” reputation likely traces to degraded terpenes in aged cannabis, not to CBN acting independently.

Does CBG help with anxiety?

A 2024 double-blind, placebo-controlled crossover trial found 20 mg of hemp-derived CBG significantly reduced anxiety and stress ratings and improved verbal recall in 34 healthy adults, without intoxicating effects. It is the only published human RCT of CBG for anxiety. Replication in larger, more diverse populations is needed before drawing firm clinical conclusions.

What does THCV do for metabolism?

In a randomized controlled trial of 62 people with type 2 diabetes, THCV improved fasting glucose and adiponectin levels compared to placebo over 13 weeks. A 2025 review concludes it may modulate appetite and glycemic control, with the caveat that larger trials are necessary to confirm those effects.

How much human research exists on minor cannabinoids overall?

Very little, relative to CBD and THC. A 2024 systematic review of minor cannabinoids in psychiatric conditions found only one qualifying clinical study across all compounds. Most available data on CBC and several others comes from preclinical animal or in vitro research. That gap is expected to narrow as Schedule I research barriers ease and clinical trials report results over the next few years.

Was this useful for you? Yes 4 No 0

Why not?

It contained inaccurate information

The information was not helpful/relevant

I couldn't find the information I was looking for easily

Thanks for your feedback!

Sign up for bi-weekly updates, packed full of cannabis education, recipes, and tips. Your inbox will love it.

Email *

Subscribe